In a groundbreaking development for cancer treatment, a 92-year-old great-grandmother from Harrogate, North Yorkshire, has become the first patient in the UK to receive a revolutionary form of therapy for an inoperable liver tumour. Brenda Iveson was initially informed that conventional treatments would not be effective against her six-centimetre tumour. However, thanks to innovative robotic-guided electrochemotherapy, her tumour has now shrunk by approximately 80%, providing a glimmer of hope for patients facing dire prognoses.
A New Approach to Cancer Treatment
After being diagnosed in late 2025, Mrs Iveson was told that traditional cancer treatments, including surgery, chemotherapy, and radiotherapy, were not viable options due to the location of her tumour and her overall health. Medical professionals at Leeds Teaching Hospitals NHS Trust, however, identified her case as suitable for a cutting-edge intervention that merges the precision of robotics with the efficacy of electrochemotherapy—a technique that combines low doses of chemotherapy with targeted electrical pulses.
Professor Tze Min Wah, who leads the interventional oncology programme at Leeds Teaching Hospitals and also holds a professorship in interventional radiology at the University of Leeds, recognised that this innovative treatment could provide a lifeline for Mrs Iveson. “This treatment allowed us to offer an option where there would otherwise have been none,” she stated, emphasising the importance of robotic precision in improving patient outcomes, especially for those with tumours in complex anatomical locations.
The Treatment Process
The procedure was executed under general anaesthetic, utilising robotic guidance to position needles accurately around the tumour. This method is particularly advantageous as it avoids the use of heat, thus minimising risks when treating tumours in proximity to vital structures, such as blood vessels and bile ducts. The Leeds Teaching Hospitals NHS Trust has announced that this is the first instance in the UK where such a treatment has been performed using robotic assistance.
Mrs Iveson expressed her relief and satisfaction with the procedure, stating, “I had been told there was nothing that could be done. So to be offered this treatment gave me real hope. I’m so glad I went ahead — it wasn’t painful or debilitating, and I feel very well.” Her experience highlights the potential for new technologies to redefine the landscape of cancer treatment, especially for elderly patients who may otherwise face limited options.
Ongoing Research and Future Implications
Currently, Leeds Teaching Hospitals NHS Trust is the sole UK institution conducting electrochemotherapy for liver cancer as part of a European research initiative. This study aims to evaluate not only the safety and effectiveness of the treatment but also its impact on patient survival rates, quality of life, and pain management. As the research progresses, the findings could significantly alter treatment protocols for liver cancer and similar conditions.
Mrs Iveson, who has enjoyed a 70-year marriage, reflected on the importance of research in advancing medical care. “Research may offer real results when there are no other options,” she noted. “You’re looked after so well, and it’s how medicine moves forward. If it helps me and future patients, then it’s worth it.” With ongoing monitoring, her medical team remains optimistic about the stability of her condition, showcasing the treatment’s effectiveness, particularly for frail elderly patients.
Why it Matters
This pioneering treatment marks a significant milestone in the fight against cancer, particularly for those deemed inoperable. The successful application of robotic-guided electrochemotherapy not only represents a leap forward in medical technology but also underscores the urgent need for continual innovation in cancer care. As the healthcare community explores the full potential of such treatments, the hope is that more patients like Mrs Iveson will benefit from advanced therapeutic options, enhancing their quality of life and extending survival in the face of challenging diagnoses.
